GSK in Joint Venture for Pediatric Vaccine - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GSK in Joint Venture for Pediatric Vaccine


ePT--the Electronic Newsletter of Pharmaceutical Technology

GlaxoSmithKline has formed a joint venture with Indian vaccines company Biological E to research and develop a six-in-one combination paediatric vaccine to help protect children in India and other developing countries from certain infectious diseases.

If the vaccine is approved, it will combine GSK’s injectable polio vaccine and Biological E’s pentavalent vaccine for diphtheria, tetanus, whooping cough, hepatitis B and hemophilus influenza type B, and could be the first vaccine of its type, according to a GSK press statement.

The vaccine is intended to reduce the number of injections for children and to improve compliance with immunisation schedules. Space at local storage facilities would also be freed up because the vaccine is intended to be a fully liquid, ready-to-use formulation with no need for additional ingredients or materials. Phase I development is expected to start in the next two years.

Each company will have a 50% stake in the joint venture and will bear the development costs. A small cash investment will be made by both companies to cover the start-up costs and further development costs will be split equally.

Completion of the transaction is expected later this year.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here